Katja Ott

Summary

Affiliation: University of Heidelberg
Country: Germany

Publications

  1. ncbi [Squamous cell carcinoma of the esophagus]
    K Ott
    Chirurgische Klinik, Universitat Heidelberg, Universitatsklinikum Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland
    Chirurg 82:974-80. 2011
  2. ncbi Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients
    Katja Ott
    Department of Surgery, University Hospital of Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany
    Int J Colorectal Dis 23:773-82. 2008
  3. ncbi Surgical factors influence the outcome after Ivor-Lewis esophagectomy with intrathoracic anastomosis for adenocarcinoma of the esophagogastric junction: a consecutive series of 240 patients at an experienced center
    Katja Ott
    Department of Surgery, University of Heidelberg, Heidelberg, Germany
    Ann Surg Oncol 16:1017-25. 2009
  4. ncbi Limited resection and free jejunal graft interposition for squamous cell carcinoma of the cervical oesophagus
    K Ott
    Department of Surgery, University of Heidelberg, Heidelberg, Germany
    Br J Surg 96:258-66. 2009
  5. ncbi Gastric cancer: surgery in 2011
    Katja Ott
    Department of Surgery, University of Heidelberg, INF 110, 69120 Heidelberg, Germany
    Langenbecks Arch Surg 396:743-58. 2011
  6. ncbi [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint]
    K Ott
    Chirurgische Klinik, Universitat Heidelberg, Heidelberg
    Chirurg 80:1028-34. 2009
  7. ncbi Induction chemotherapy in Barrett cancer: influence on surgical risk and outcome
    Joerg R Siewert
    Department of Surgery, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Ann Surg 246:624-8; discussion 628-31. 2007
  8. ncbi Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction
    Katja Ott
    Department of Surgery, Technische Universitaet Muenchen, Ismaningerstr 22, D 81675, Munich, Germany
    J Clin Oncol 24:4692-8. 2006
  9. ncbi Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer
    Katja Ott
    Department of Surgery, University of Heidelberg, Heidelberg, Germany
    Ann Surg Oncol 18:3316-23. 2011
  10. ncbi DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy
    Katja Ott
    Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
    Ann Surg Oncol 18:2688-98. 2011

Detail Information

Publications26

  1. ncbi [Squamous cell carcinoma of the esophagus]
    K Ott
    Chirurgische Klinik, Universitat Heidelberg, Universitatsklinikum Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland
    Chirurg 82:974-80. 2011
    ..Responding patients should be transferred to surgery after preoperative treatment, because of a reduced perioperative morbidity and mortality and improved prognosis...
  2. ncbi Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients
    Katja Ott
    Department of Surgery, University Hospital of Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany
    Int J Colorectal Dis 23:773-82. 2008
    ..Therefore, glutathione-S-transferase (GST) polymorphisms were assessed as predictive markers in cisplatinum-based neoadjuvant-treated gastric cancer...
  3. ncbi Surgical factors influence the outcome after Ivor-Lewis esophagectomy with intrathoracic anastomosis for adenocarcinoma of the esophagogastric junction: a consecutive series of 240 patients at an experienced center
    Katja Ott
    Department of Surgery, University of Heidelberg, Heidelberg, Germany
    Ann Surg Oncol 16:1017-25. 2009
    ..Thus, we evaluated the surgical risk and outcome after an abdominothoracic esophagectomy (Ivor-Lewis) with intrathoracic anastomosis as standard procedure...
  4. ncbi Limited resection and free jejunal graft interposition for squamous cell carcinoma of the cervical oesophagus
    K Ott
    Department of Surgery, University of Heidelberg, Heidelberg, Germany
    Br J Surg 96:258-66. 2009
    ..Treatment options range from definitive radiotherapy to multimodal treatment. Outcome after limited resection and reconstruction with a free jejunal graft interposition was evaluated retrospectively...
  5. ncbi Gastric cancer: surgery in 2011
    Katja Ott
    Department of Surgery, University of Heidelberg, INF 110, 69120 Heidelberg, Germany
    Langenbecks Arch Surg 396:743-58. 2011
    ..Individualized resection and lymphadenectomy techniques for early tumor stages and response-based neoadjuvant concepts for locally advanced tumors are the challenge for the future...
  6. ncbi [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint]
    K Ott
    Chirurgische Klinik, Universitat Heidelberg, Heidelberg
    Chirurg 80:1028-34. 2009
    ..Patients with locally advanced gastric cancer should always be referred to experienced high volume centers, where the findings are discussed in a multidisciplinary tumor board...
  7. ncbi Induction chemotherapy in Barrett cancer: influence on surgical risk and outcome
    Joerg R Siewert
    Department of Surgery, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Ann Surg 246:624-8; discussion 628-31. 2007
    ..To study the impact of induction chemotherapy on surgical risk and outcome in locally advanced Barrett cancer...
  8. ncbi Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction
    Katja Ott
    Department of Surgery, Technische Universitaet Muenchen, Ismaningerstr 22, D 81675, Munich, Germany
    J Clin Oncol 24:4692-8. 2006
    ..The aim of this study was to prospectively validate these findings by using an a priori definition of metabolic response...
  9. ncbi Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer
    Katja Ott
    Department of Surgery, University of Heidelberg, Heidelberg, Germany
    Ann Surg Oncol 18:3316-23. 2011
    ..In this study we tested whether FLT-positron emission tomography (PET) can improve the predictive potential of molecular imaging for assessing response to neoadjuvant therapy in gastric cancer compared with FDG-PET...
  10. ncbi DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy
    Katja Ott
    Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
    Ann Surg Oncol 18:2688-98. 2011
    ..We assessed 12 polymorphisms in 7 DNA repair genes and 2 polymorphisms in the MTHFR gene for association with disease response and prognosis...
  11. ncbi Prognostic significance of free peritoneal tumor cells in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric carcinoma undergoing potentially curative resection
    Sylvie Lorenzen
    National Center of Tumor Diseases, University of Heidelberg, Heidelberg, Germany
    Ann Surg Oncol 17:2733-9. 2010
    ..Whether neoadjuvant chemotherapy (NAC) can eliminate FPTCs in the peritoneal lavage remains unclear. The aim of the study was to determine the effect of NAC on FPTCs...
  12. ncbi PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
    Florian Lordick
    Department of Surgery, Clinic rechts der Isar, Technical University of Munich, Munich, Germany
    Lancet Oncol 8:797-805. 2007
    ..We aimed to assess the feasibility of a PET-response-guided treatment algorithm and its potential effect on prognosis...
  13. ncbi Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study
    Katja Ott
    Department of Surgery, Technische Universitat Munchen, Munich, Germany
    Clin Cancer Res 14:2012-8. 2008
    ..The goal of the study was the definition of biologically different groups of patients prior to or early during induction therapy, with special emphasis on FDG non-avid tumors...
  14. ncbi Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial
    Katja Ott
    Department of Surgery, Technische Universitä München, Munich, Germany
    J Clin Oncol 21:4604-10. 2003
    ..We prospectively evaluated the predictive value of therapy-induced reduction of tumor glucose use for subsequent response and patient survival in patients with gastric cancer treated by preoperative chemotherapy...
  15. ncbi The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies
    Katja Ott
    Department of Surgery, University of Heidelberg, Im Neuenheimer Feld 110, Heidelberg, Germany
    Gastric Cancer 11:1-9. 2008
    ....
  16. ncbi Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study
    Katja Ott
    Department of Surgery, , Ismaninger Str. 22, 81675 Munich, Germany
    Gastric Cancer 6:159-67. 2003
    ..The development of peritoneal dissemination even after neoadjuvant chemotherapy and complete resection remains an unsolved problem in patients with nonintestinal type tumors...
  17. ncbi Association of the VEGF 936C>T polymorphism with FDG uptake, clinical, histopathological, and metabolic response in patients with adenocarcinomas of the esophagogastric junction
    Sylvie Lorenzen
    National Center of Tumor Diseases, University of Heidelberg, Heidelberg, Germany
    Mol Imaging Biol 13:178-86. 2011
    ..An association of the vascular endothelial growth factor (VEGF) 936C>T polymorphism and FDG uptake was reported for breast cancer. Therefore, we investigated the VEGF 936C>T polymorphism for an association with response and survival...
  18. ncbi Paclitaxel in the neoadjuvant treatment for adeno carcinoma of the distal esophagus (AEG I). A comparison of two phase II trials with long-term follow-up
    Franz G Bader
    Department of Surgery, University of Schleswig Holstein, Campus Lubeck, Germany
    Onkologie 31:366-72. 2008
    ..We report a comparative analysis of 2 sequential, prospective phase II trials on the efficacy of platinum/leucovorin/5-fluorouracil (PLF) +/- paclitaxel (T-PLF) in the neoadjuvant treatment of adenocarcinoma of the esophagus (AEG I)...
  19. ncbi Impact of pretherapeutic routine clinical staging for the individualization of treatment in gastric cancer patients
    Susanne Blank
    Surgical Department, University Hospital Heidelberg, INF 110, Heidelberg, 69120, Germany
    Langenbecks Arch Surg 397:45-55. 2012
    ..Our aim was to compare clinical and histopathological staging and to analyze the predictive value of routine clinical staging and its significance for the individualization of treatment...
  20. ncbi Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia
    Katja Ott
    Department of Surgery, Klinikum rechts der Isar, Technical University Munich, Ismaningerstrasse 22, D-81675 Munich, Germany
    World J Surg 27:1035-9. 2003
    ..This finding strengthens the hypothesis that AEG I and AEG II are two different tumor entities...
  21. ncbi The thymidylate synthase tandem repeat promoter polymorphism: A predictor for tumor-related survival in neoadjuvant treated locally advanced gastric cancer
    Katja Ott
    Department of Surgery, Technical University, Munich, Germany
    Int J Cancer 119:2885-94. 2006
    ..93). Patients' survival after CTx was associated with the TS tandem repeat polymorphism. CTx did not improve survival of patients with the 3rpt/3rpt genotype. Thus, a different therapy might be more appropriate for these patients...
  22. ncbi Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma
    Katja Ott
    Department of Surgery, Klinikum rechts der Isar, , D-81675 Munich, Germany
    Clin Cancer Res 9:2307-15. 2003
    ..p53 mutation status is not significantly associated with therapy response and is not a useful marker for response prediction...
  23. ncbi The Value of PET Imaging in Patients with Localized Gastroesophageal Cancer
    Katja Ott
    Department of Surgery, University of Heidelberg, Heidelberg, Germany
    Gastrointest Cancer Res 2:287-94. 2008
    ....
  24. ncbi The evolving role of catumaxomab in gastric cancer
    Florian Lordick
    University of Heidelberg, National Center for Tumour Diseases, Department of Medical Oncology, Im Neuenheimer Feld 350, 69120 Heidelberg, Germany
    Expert Opin Biol Ther 8:1407-15. 2008
    ..Intraperitoneal administration of catumaxomab in patients with malignant ascites due to epithelial cancer significantly increased puncture-free survival...
  25. ncbi Are squamous and adenocarcinomas of the esophagus the same disease?
    J Rudiger Siewert
    Department of Surgery, Klinikum rechts der Isar, Technische Universitat, Munchen, Germany
    Semin Radiat Oncol 17:38-44. 2007
    ..We suggest that the two different tumor entities should be analyzed and reported separately to provide comparable results in the future...
  26. ncbi European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer
    Florian Lordick
    National Centre for Tumour Diseases, Department of Medical Oncology, University of Heidelberg, Im Neuenheimer Feld 350, 69120 Heidelberg, Germany
    Eur J Cancer 44:1807-19. 2008
    ..This paper reviews the lectures and discussions held during this workshop and summarises the action points for the further investigation of metabolic imaging to guide treatment in gastrointestinal tumours...